Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors

Annals of Hematology

Volumn 91, Issue 3, 2012, Pages 391-397

  Schmitt, Christian Johannes ^a   Dietrich, Sascha ^a   Ho, Antony Dick ^a   Witzens Harig, Mathias ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Caelyx; Cardiac comorbidity; Liposomal pegylated doxorubicin; Lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGE; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; CONGESTIVE CARDIOMYOPATHY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; GREAT VESSELS TRANSPOSITION; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART ATRIUM FLUTTER; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INFECTION; INTERNATIONAL PROGNOSTIC INDEX; ISCHEMIC HEART DISEASE; LARGE CELL LYMPHOMA; LUNG EMBOLISM; MALE; MANTLE CELL LYMPHOMA; MITRAL VALVE REGURGITATION; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; POOR GENERAL CONDITION; PRIORITY JOURNAL; PROGNOSIS; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; T CELL LYMPHOMA;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOVASCULAR DISEASES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; POLYETHYLENE GLYCOLS; PREDNISONE; REMISSION INDUCTION; RISK FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84857357728     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1308-y     Document Type: Article

References (34)

1. A Antón A Ruiz MA Seguí L Calvo M Muñoz J Lao F Sancho L Fernández 2009 Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study Ann Oncol 20 454 459 19074216 10.1093/annonc/mdn663 Epub 2008 Dec 11
2. A Antón A Ruiz A Plazaola L Calvo MA Seguí A Santaballa M Muñoz P Sánchez A Miguel E Carrasco J Lao J Camps J Alfaro S Antolín MC Cámara 2010 Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study Ann Oncol 22 74 79 20603435 10.1093/annonc/mdq317
3. BR Baack WH Burgdorf 1991 Chemotherapy-induced acral erythema J Am Acad Dermatol 24 457 461 2061446 10.1016/0190-9622(91)70073-B 1:STN:280: DyaK3M3os1Cltg%3D%3D
4. JS Beard KJ Smith HG Skelton 1993 Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic features of graft-versus-host disease J Am Acad Dermatol 29 325 330 8340507 10.1016/0190-9622(93)70187-X 1:STN:280:DyaK3szktVeitw%3D%3D (Pubitemid 23221936)
5. E Brusamolino C Rusconi L Montalbetti L Gargantini L Uziel G Pinotti S Fava L Rigacci G Pagnucco C Pascutto E Morra M Lazzarino 4 2006 Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity Haematologica 91 496 502 16537117 1:CAS:528:DC%2BD28XkslOku7g%3D Epub 2006 Mar 15
6. BD Cheson SJ Horning B Coiffier MA Shipp RI Fisher JM Connors TA Lister J Vose A Grillo-López A Hagenbeek F Cabanillas D Klippensten W Hiddemann R Castellino NL Harris JO Armitage W Carter R Hoppe GP Canellos 1999 Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 4 1244 10561185 1:STN:280:DC%2BD3c%2FivF2itg%3D%3D
7. B Coiffier E Lepage J Briere, et al. 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235 242 11807147 10.1056/NEJMoa011795 1:CAS:528:DC%2BD38XmslGgsw%3D%3D (Pubitemid 34438862)
8. RE Coleman L Biganzoli P Canney, et al. 2006 A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993) Eur J Cancer 42 882 887 16520033 10.1016/j.ejca.2005.12.011 1:CAS:528:DC%2BD28XksVOitLY%3D
9. F de Nigris M Rienzo C Schiano C Fiorito A Casamassimi C Napoli 2008 Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart Eur J Cancer 44 3 334 340 18194856 10.1016/j.ejca.2007.12.010
10. DA Gewirtz 1999 A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin Biochem Pharmacol 57 7 727 741 10075079 10.1016/S0006-2952(98) 00307-4 1:CAS:528:DyaK1MXhsFeksL8%3D (Pubitemid 29094544)
11. E Gimeno B Sánchez-González A Alvarez-Larrán C Pedro E Abella J Comín S Saumell F García-Pallarols M Gómez C Besses A Salar 2011 Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma Leuk Res 35 358 362 20708263 10.1016/j.leukres.2010.07.024 1:CAS:528:DC%2BC3MXjs1Sntrc%3D
12. L Harris G Batist R Belt D Rovira R Navari N Azarnia L Welles E Winer TLC D-99 Study Group 2002 Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma Cancer 94 1 25 36 11815957 10.1002/cncr.10201 1:CAS:528:DC%2BD38XlslKgsw%3D%3D (Pubitemid 34049039)
13. D Heintel C Skrabs A Hauswirth K Eigenberger C Einberger M Raderer WR Sperr P Knöbl L Müllauer M Uffmann K Dieckmann A Gaiger U Jäger 2010 Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age Ann Hematol 89 2 163 169 19636553 10.1007/s00277-009-0796-5 1:CAS:528:DC%2BC3cXjt1yktg%3D%3D
14. RM Lang M Bierig RB Devereux FA Flachskampf E Foster PA Pellikka MH Picard MJ Roman J Seward J Shanewise S Solomon KT Spencer M St John Sutton W Stewart 2 2006 American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification Eur J Echocardiogr 7 79 108 16458610 10.1016/j.euje.2005.12.014 (Pubitemid 43257193)
15. EA Lefrak J Pitha S Rosenheim JA Gottlieb 1973 A clinicopathologic analysis of Adriamycin cardiotoxicity Cancer 32 302 314 4353012 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2 1:STN:280:DyaE3s3jtVWquw%3D%3D
16. D Lorusso A Naldini A Testa G D'Agostino G Scambia G Ferrandina 2004 Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile? Oncology 67 243 249 15557785 10.1159/000081324 1:CAS:528:DC%2BD2cXhtVWjtrfO (Pubitemid 39551708)
17. E Nagore A Insa O Sanmartin 2000 Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management Am J Clin Dermatol 1 225 234 11702367 10.2165/00128071-200001040- 00004 1:STN:280:DC%2BD3MnltVCjug%3D%3D
18. ME O'Brien N Wigler M Inbar R Rosso E Grischke A Santoro R Catane DG Kieback P Tomczak SP Ackland F Orlandi L Mellars L Alland C Tendler 2004 CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann Oncol 15 3 440 449 14998846 10.1093/annonc/mdh097 (Pubitemid 38444547)
19. MJ Parr D Masin PR Cullis MB Bally 1997 Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol) J Pharmacol Exp Ther 280 3 1319 1327 9067319 1:CAS:528:DyaK2sXhvF2mtbw%3D (Pubitemid 27166729)
20. M Pfreundschuh L Trümper A Osterborg R Pettengell M Trneny K Imrie D Ma D Gill J Walewski PL Zinzani R Stahel S Kvaloy O Shpilberg U Jaeger M Hansen T Lehtinen A López-Guillermo C Corrado A Scheliga N Milpied M Mendila M Rashford E Kuhnt M Loeffler MabThera International Trial Group 2006 CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 379 391 16648042 10.1016/S1470-2045(06)70664-7 1:CAS:528:DC%2BD28XjvFWlsbw%3D
21. M Pfreundschuh J Schubert M Ziepert R Schmits M Mohren E Lengfelder M Reiser C Nickenig M Clemens N Peter C Bokemeyer H Eimermacher A Ho M Hoffmann R Mertelsmann L Trümper L Balleisen R Liersch B Metzner F Hartmann B Glass V Poeschel N Schmitz C Ruebe AC Feller M Loeffler German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) 2008 Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Lancet Oncol 9 2 105 116 18226581 10.1016/S1470-2045(08)70002-0 1:CAS:528:DC%2BD1cXhsVOnu7g%3D
22. PG Rose 2005 Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer Oncologist 10 3 205 214 15793224 10.1634/ theoncologist.10-3-205 1:CAS:528:DC%2BD2MXjsFSnsbg%3D (Pubitemid 40463158)
23. A Rueda P Sabin J Rifá M Llanos J Gómez-Codina F Lobo R García J Herrero M Provencio C Jara 2008 Grupo Oncológico para el Tratamiento y Estudio de los Linfomas (GOTEL) R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study Hematol Oncol 26 1 27 32 17868190 10.1002/hon.829 1:CAS:528:DC%2BD1cXkslyqt7g%3D (Pubitemid 351448908)
24. T Safra 2003 Cardiac safety of liposomal anthracyclines Oncologist 8 Suppl 2 17 24 13679592 10.1634/theoncologist.8-suppl-2-17 1:CAS:528: DC%2BD3sXotF2qt7g%3D (Pubitemid 37152053)
25. T Simůnek M Stérba O Popelová M Adamcová R Hrdina V Gersl 1 2009 Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron Pharmacol Rep 61 154 171 19307704
26. SM Swain FS Whaley MC Gerber S Weisberg M York D Spicer SE Jones S Wadler A Desai C Vogel J Speyer A Mittelman S Reddy K Pendergrass E Velez-Garcia MS Ewer JR Bianchine RA Gams 1997 Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer J Clin Oncol 15 4 1318 1332 9193323 1:CAS:528:DyaK2sXivVeiu7c%3D (Pubitemid 27167363)
27. Z Symon A Peyser D Tzemach E Lyass E Sucher E Shezen A Gabizon 1999 Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes Cancer 86 1 72 78 10391566 10.1002/(SICI)1097- 0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1 1:CAS:528:DyaK1MXktleqtLc%3D (Pubitemid 29293379)
28. G Takemura H Fujiwara 5 2007 Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management Prog Cardiovasc Dis 49 330 352 17329180 10.1016/j.pcad.2006.10.002 1:CAS:528:DC%2BD2sXktFKqsLc%3D (Pubitemid 46295436)
29. N Tsavaris C Kosmas M Vadiaka S Giannouli MP Siakantaris T Vassilakopoulos GA Pangalis 3 2002 Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma Anticancer Res 22 1845 1848 12168880 1:CAS:528:DC%2BD38XmsFWktbs%3D (Pubitemid 34839207)
30. EC van Dalen EM Michiels HN Caron LC Kremer 2010 Different anthracycline derivates for reducing cardiotoxicity in cancer patients Cochrane Database Syst Rev 5 CD005006 20464735
31. DD Von Hoff MW Layard P Basa HL Davis Jr AL Von Hoff M Rozencweig FM Muggia 1979 Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 5 710 717 (Pubitemid 10218041)
32. DN Waterhouse PG Tardi LD Mayer MB Bally 2001 A comparison of liposomal formulations of doxorubicin with drug administered in free form Drug Saf 24 12 903 920 11735647 10.2165/00002018-200124120-00004 1:CAS:528:DC%2BD3MXptVyisrc%3D (Pubitemid 33078196)
33. ET Yeh AT Tong DJ Lenihan SW Yusuf J Swafford C Champion JB Durand H Gibbs AA Zafarmand MS Ewer 2004 Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management Circulation 109 25 3122 3131 15226229 10.1161/01.CIR.0000133187.74800.B9
34. F Zaja V Tomadini A Zaccaria M Lenoci M Battista AL Molinari A Fabbri R Battista MG Cabras A Gallamini R Fanin 2006 CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma Leuk Lymphoma 47 10 2174 2180 17071492 10.1080/10428190600799946 1:CAS:528:DC%2BD28XhtlCiu7%2FP (Pubitemid 44650095)